Abstract

Metabolic dysfunction, commonly a result of diets high in saturated fats and sugar, is associated with impaired cognitive function and an increased risk of age-related cognitive decline (ACD) and Alzheimer’s disease (AD). Compared to the E3 isoform of apolipoprotein (apoE), the E4 isoform is a major genetic risk factor for ACD, AD, and for developing cognitive impairments following various environmental challenges, including dietary challenges such as a high-fat diet (HFD). Both insulin resistance (IR) and E4 are associated with metabolic and vascular impairments. Deficits in cerebral metabolism and cerebrovascular function have been proposed as initiating events leading to these impairments. In the current study, we employed a model of human apoE targeted replacement mice and HFD-induced obesity to study the potential link between E4 and IR, at rest and following a postprandial challenge. HFD-induced IR was associated with impaired cognition, reduced cerebral blood volume and decreased glucose uptake. These effects were more profound in E4 than E3 mice. Furthermore, the cognitive, metabolic and cerebrovascular responses to an exogenous glucose load showed an apoE isoform-dependent response, with E4, but not E3 mice, acutely benefiting from a spike in blood glucose.

Document Type

Article

Publication Date

5-1-2019

Notes/Citation Information

Published in Journal of Cerebral Blood Flow & Metabolism, v. 39, issue 5, p. 770-781.

© Author(s) 2017

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Digital Object Identifier (DOI)

https://doi.org/10.1177/0271678X17746186

Funding Information

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: LAJ was supported by NIH grant T32-HL094294, NSF grant SMA-1408653, the Oregon Tax Check-off Program for Alzheimer’s Research administered by the Layton Aging & Alzheimer’s Disease Center at OHSU, the Collins Medical Trust in Portland, OR, and an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103527. NJA was supported by NIH R21AG043857. JR is supported by 1R56AG057495-01.

Related Content

Supplementary material for this paper can be found at the journal website: http://journals.sagepub.com/home/jcb

supplementary_material.pdf (126 kB)
Supplementary Material

Share

COinS